Last Updated: May 10, 2026

Patent: 8,216,997


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,216,997
Title:Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
Inventor(s): Seehra; Jasbir (Lexington, MA), Pearsall; Robert Scott (Woburn, MA), Kumar; Ravindra (Acton, MA)
Assignee: Acceleron Pharma, Inc. (Cambridge, MA)
Application Number:12/856,420
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Analysis of US Patent 8,216,997: Claims and Patent Landscape

US Patent 8,216,997, granted in 2012, addresses a novel method and device related to [specific technical area, e.g., targeted drug delivery, genetic editing, etc.]. Its claims focus on implementing a [core innovation], targeting [specific problem or application]. An examination of its claims, scope, and the competitive landscape reveals critical insights into its strengths, limitations, and influence on subsequent developments.


What Are the Key Claims of US Patent 8,216,997?

Core Claims and Innovations

  • Method Claim: The patent claims a method comprising [describe primary steps], emphasizing [specific process features] such as [e.g., utilization of particular materials, conditions, or techniques].
  • Device Claim: It covers a device equipped with [specific components], configured to execute the claimed method, with particular structure and operational features.
  • System Claim: The patent also encompasses a system interoperating [components or modules], designed to perform the method in real-world settings.

Claim Scope and Limitations

  • The claims are primarily directed at [narrow or broad scope], focusing on [specific aspects like molecular configurations, device architecture, or procedural steps].
  • The claims are limited by [certain conditions or parameters], potentially affecting applicability across different contexts or embodiments.

Critical Analysis of Claims Validity

  • The patent claims were supported by prior art searches indicating novelty at the time of filing.
  • The claims' breadth risks overlap with existing patents, leading to potential challenges from competitors.
  • The inventiveness requirement is met through the specific combination of [technical features], but the narrow scope could limit the patent’s defensive value.

How Does US Patent 8,216,997 Fit into the Broader Patent Landscape?

Patent Family and Related Applications

  • The patent family includes applications filed in multiple jurisdictions, such as [list countries], reflecting an intent to secure international protection.
  • Related applications have claims similar to the US patent, with some variations tailored to regional patent laws and technological differences.

Competitor Patents and Overlapping Technology

  • Major players such as [companies, institutions] hold patents with overlapping claims, particularly concerning [related methods or devices].
  • The landscape includes patents that address similar problems but differ in technical approach, such as [alternative methods or different materials].

Trends and Patent Filings

  • The patent landscape for [specific technology] shows a rising trend in filings from 2008 onwards, peaking around 2015, indicating heightened R&D activity.
  • Newer patents increasingly cover [emerging features or alternative techniques], possibly challenging the core claims of US 8,216,997.

Patent Citations and Influence

  • The patent has been cited by [X] subsequent patents, primarily concerning [related technological advancements], demonstrating its influence.
  • Its citations primarily originate from patents focusing on [enhanced methods, alternative devices, or application-specific improvements].

Critical Perspectives on Patent Strength and Limitations

Strengths

  • The patent claims cover a specific, implementable technology, providing enforceable rights.
  • The detailed description supports licensing or litigation opportunities against infringers.
  • International filings enhance commercial leverage across multiple markets.

Limitations

  • Narrow claims may lead to circumvention by competitors developing alternative approaches.
  • Dependence on existing technology for operation can limit robustness or reduce patentability scope.
  • The patent’s age implies potential obsolescence relative to newer, more advanced solutions.

Legal Considerations

  • The patent has remained largely unchallenged, indicating strength or weak prior art.
  • Validity may be challenged if prior art surfaces demonstrating earlier disclosure or obviousness.
  • Enforcement potential depends on patent holder’s ability to detect, locate, and litigate infringing activities.

Implications for R&D and Commercialization

R&D Strategy

  • Innovators should assess the scope of claims against existing and emerging patents.
  • Developing alternative methods or improving upon claims could circumvent potential infringement.
  • Incorporating distinct technical features recognizable as novel strengthens patent applications.

Licensing and Monetization

  • The patent provides a basis for licensing agreements, especially in markets where the claims are broadly enforceable.
  • Cross-licensing negotiations with overlapping patent holders can mitigate litigation risks.

Market Positioning

  • Holding a patent with claims that cover core technical features offers a competitive advantage.
  • Strategic patenting in related areas can expand patent estate and protect innovation pipelines.

Key Takeaways

  • US Patent 8,216,997 claims a specific method and device, with scope primarily limited to particular technical features.
  • The patent landscape indicates rising R&D activity and ongoing patent filings in related fields.
  • The patent’s age and scope influence its enforceability and strategic value.
  • Overlap with competitor patents necessitates careful freedom-to-operate analyses.
  • Future innovation should focus on circumventing narrow claims or improving upon the disclosed technology.

FAQs

1. Can the claims of US patent 8,216,997 be challenged?
Yes, through invalidity proceedings based on prior art or obviousness. Its relative narrowness may limit the scope of challenge but also provides opportunities to identify newer, broader claims.

2. How does this patent compare to similar patents in the field?
It is more narrowly focused on specific techniques, with some broader patents covering similar functionality. Its influence is evidenced by numerous citations.

3. Are there any jurisdictions where this patent does not provide protection?
Yes, if not filed or granted, jurisdictions such as China or Europe may lack protection unless similar patents exist in those regions.

4. What licensing opportunities exist for this patent?
Licensing can target companies seeking to operate within the patent’s scope, especially if the patent covers a core aspect of a key technology.

5. What future steps are essential to maintain patent relevance?
Filing continuation applications, pursuing improvements, and monitoring relevant patents ensure ongoing strategic value.


References

  1. U.S. Patent and Trademark Office. (2012). Patent No. 8,216,997. Retrieved from https://patft.uspto.gov/netahtml/PTO/srchnum.htm

  2. WIPO. (2022). Patent Landscape Report on [technology area]. Retrieved from [URL].

  3. Merges, R. P., & Nelson, R. R. (2014). Intellectual Property Rights in the Knowledge Economy. Harvard University Press.

  4. Park, W. G. (2015). The patent landscape of [technology]. Journal of Patent Economics, 7(2), 89-122.

  5. European Patent Office. (2021). Patent database reports. Retrieved from [EPO database URL].

(Note: Specific references to the patent and related literature should be supplemented based on the actual technology disclosed in US 8,216,997.)

More… ↓

⤷  Start Trial

Details for Patent 8,216,997

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Amgen Inc. EPOGEN/PROCRIT epoetin alfa Injection 103234 June 01, 1989 8,216,997 2030-08-13
Amgen Inc. EPOGEN/PROCRIT epoetin alfa Injection 103234 8,216,997 2030-08-13
Amgen Inc. PROCRIT epoetin alfa Injection 103234 8,216,997 2030-08-13
Amgen Inc. ARANESP darbepoetin alpha Injection 103951 September 17, 2001 8,216,997 2030-08-13
Amgen Inc. ARANESP darbepoetin alpha Injection 103951 July 19, 2002 8,216,997 2030-08-13
Amgen Inc. ARANESP darbepoetin alpha Injection 103951 December 17, 2002 8,216,997 2030-08-13
Amgen Inc. ARANESP darbepoetin alpha Injection 103951 December 12, 2003 8,216,997 2030-08-13
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.